arrow
D

David M. Smadja

INSERM
H指数:50
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Soluble ST2 dynamics are associated with delayed hospital discharge in COVID-19 patients: a joint-modeling analysis of the DisCoVeRy trial’s longitudinal data.

可溶性ST2动力学与COVID-19患者延迟出院相关:DisCoVeRy试验纵向数据的联合建模分析

2026-08-070
PRE
Optimized Metabolic Conditions Reveal the Adipogenic Competence of Wharton’s Jelly MSCs: Insight from Literature Review and Experimental Validation

优化代谢条件揭示沃顿胶间充质干细胞的脂肪生成能力:来自文献综述和实验验证的见解

2026-07-230
OA
Extracellular vesicles as key biomarkers in COVID-19: insights into disease severity and mortality through CD86 and other immune markers

细胞外囊泡作为COVID-19中的关键生物标志物:通过CD86和其他免疫标志物对疾病严重程度和死亡率的认识

2026-03-230
OA
AI-Enhanced Dermoscopy for Early Skin Cancer Detection in Private Practice: Insights from a Retrospective Cohort Study

AI增强的皮肤镜在私人诊所中用于早期皮肤癌检测:一项回顾性队列研究的见解

2025-12-170
PRE
Hydroxychloroquine does not affect endotheliopathy or coagulopathy biomarkers in COVID-19: longitudinal results from the DisCoVeRy randomized trial

羟氯喹对COVID-19的血管内皮功能障碍或凝血功能障碍生物标志物无影响:DisCoVeRy随机试验的纵向结果

2025-12-070
OAAI
Prevention of Hemorrhage After Implantation of Mechanical Circulatory Support With a Purified Von Willebrand Factor Concentrate: results of the early terminated randomized controlled PHAM trial

机械循环支持植入术后出血的预防:使用纯化血管性血友病因子浓缩物的早期终止随机对照PHAM试验结果

2025-10-080
PRE
Safety of venetoclax in real-world experience: data from the French national database of pharmacovigilance through all indications in hematological malignancies over 5 years

venetoclax在真实世界经验中的安全性:来自法国全国药物警戒数据库的数据,涵盖5年内血液系统恶性肿瘤的所有适应症。

2025-07-290
OA